– USA, PA – Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) today announced the appointment of Dr. Barbara Ruskin (Ph.D. / J.D.) to its Board of Directors, increasing the Board to nine members.
“With her unique background, knowledge, and experience, we believe that Dr. Ruskin will be a valuable addition to our Board. We are very pleased that she is joining us and look forward to her contributions,” said Chairman and CEO, Tony Mack,.
About Dr. Barbara A. Ruskin
Dr. Ruskin, who received her Ph.D. in Biochemistry & Molecular Biology from Harvard University, is an experienced attorney specializing in life sciences and intellectual property. Most recently she serves as the Chief Intellectual Property and Innovation Officer for Silence Therapeutics, a Nasdaq-listed international biotechnology company. Before that role, she was the Company’s, General Counsel and Chief Patent Officer. Dr. Ruskin brings over 25 years of experience in life science IP and corporate law, having served as outside counsel for pharmaceutical and biotechnology companies and their investors, including as an IP Corporate Partner at Ropes & Gray LLP and as an associate at Fish & Neave LLP, both in New York City. She has advised, managed, and prosecuted worldwide patent portfolios for several biotech and pharmaceutical industry clients including Biogen, Stryker Biotech, and Vertex Pharmaceuticals among others. She has also worked in IP litigation in both the U.S. and Europe. Dr. Ruskin previously served as Chairman and currently serves as a director on the Board of St. Jude Children’s Hospital GMP, LLC, and has previously served as a director on the Board of the Burke Neurological Institute.
Dr. Ruskin did her post-doctoral research at the Whitehead Institute for Biomedical Research and at the Institute for Neuroscience (University of Oregon). She has published numerous scientific articles and given legal presentations that combine her knowledge of biochemistry and law. In addition to her Ph.D. in Biochemistry & Molecular Biology, Dr. Ruskin received a B.A. from the University of California, Berkeley, and her J.D. from Fordham University School of Law.
About Virpax Pharmaceuticals
Virpax is developing branded, non-addictive pain management product candidates using its proprietary technologies to optimize and target drug delivery. Virpax is initially seeking FDA approval for two prescription drug candidates that employ two different patented drug delivery platforms. Probudur is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain and Envelta is an intranasal molecular envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. Virpax also uses its intranasal Molecular Envelope Technology to develop two other product candidates. PES200 is a product candidate being developed to manage post-traumatic stress disorder and NobrXiol is a product candidate being developed for the nasal delivery of pharmaceutical-grade cannabidiol for the management of rare pediatric epilepsy. Virpax recently acquired global rights to NobrXiol. Virpax is also seeking approval for two nonprescription product candidates: AnQlar, which is being developed to inhibit viral replication caused by influenza or SARS-CoV-2, and Epoladerm, which is a topical diclofenac spray film formulation being developed to manage pain associated with osteoarthritis.
Source: https://virpaxpharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
